drug · oligonucleotide
elebsiran
Phase 3updated 6mo agoby $VIR Vir Biotechnology, Inc.🔗 ChEMBL
Phase 3community read0 votes
Oligonucleotide drug with a maximum clinical stage of Phase 2 (across all indications), with 5 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying elebsiran
News(7)
- Vir's hepatitis delta combo tamps down virus as Gilead showdown loomsVir Biotechnology is targeting a mid-2027 regulatory submission for its monthly chronic hepatitis delta regimen, with head-to-head data against Gilead’s Hepcludex expected next quarter.biospace · 7d ago
- Vir hepatitis D drug succeeds in first pivotal studyA program that’s survived Vir’s pivot away from infectious disease research hit all of its study objectives and appeared more potent than a rival drug also in late-stage development.biopharma_dive · 7d ago
- Vir’s phase 3 hepatitis delta win fuels push to eclipse GileadVir Biotechnology’s phase 3 trial in chronic hepatitis delta has hit its primary endpoint, giving the biotech the first piece of the package it needs to file for FDA approval next year.fiercebiotech · 8d ago
- GSK, Ionis hepatitis B functional cure breaks open market for followersThe approval of Hibsago has created a new market for a handful of biopharmas, including Gilead, Arrowhead, and Vir, to fill in.biospace · 25d ago
- Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagersThe Gilead Sciences deal, which include $135 million in upfront and near-term payments, marks a critical platform validation for Vir Biotechnology as investors await an upcoming readout in solid tu…biospace · 1mo ago
- Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEsLooking to expand its oncology portfolio, Gilead has tapped Vir Biotechnology’s masked T-cell engager tech in a potential $1.9 billion biobucks deal.fiercebiotech · 1mo ago
- Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, VirA phase 3 trial of Mirum Pharmaceuticals’ chronic hepatitis delta virus drug candidate has hit its primary endpoint, furthering the biotech’s efforts to enter a space recently colonized by Gilead S…fiercebiotech · 1mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that